Dogwood Therapeutics DWTX

Dogwood Therapeutics, Inc. is a prerevenue development stage biopharmaceutical company focused on creating new medicines to treat pain and neuropathy. The company's pipeline centers on the Halneuron program which modulates the voltage gated sodium channel Na v 1.7 to produce analgesic effects without opioid activity. Another pipeline asset is the SP16 program a synthetic peptide designed to activate the low density lipoprotein receptor related protein 1 pathway to reduce neuroinflammation and promote neuronal repair. Additionally the company holds antiviral assets IMC-1 and IMC-2 that target herpesvirus mediated conditions such as fibromyalgia and long COVID. All programs are at various preclinical or clinical stages with the Halneuron program in advanced clinical testing for chemotherapy induced neuropathic pain.

Dogwood Therapeutics, Inc. does not currently generate product sales revenue as its candidates remain investigational. The company finances its operations through research grants equity offerings and licensing agreements. For example the SP16 program receives full funding for its planned Phase 1b study from a grant awarded by the National Cancer Institute. The company also holds an exclusive licensing agreement with Serpin Pharma Inc. that provides rights to develop an intravenous formulation of SP16. Additional capital has been raised via registered direct offerings such as the March 2025 offering and the January 2026 offering which together generated millions of dollars in gross proceeds. These sources supply the cash needed to conduct clinical trials manufacture drug substance and support general corporate activities.

Dogwood Therapeutics, Inc. occupies a niche within the pain management sector by pursuing a nonopioid Na v 1.7 directed therapy for chemotherapy induced neuropathic pain a condition that currently lacks any FDA approved treatment. While existing off label options such as gabapentin pregabalin duloxetine and opioids are commonly used they offer limited efficacy and carry safety concerns particularly addiction risk for opioids. The company's advantage lies in its proprietary chemistry around tetrodotoxin derivatives and its extensive patent portfolio covering formulation manufacturing and use of Halneuron. The SP16 asset further differentiates the pipeline by targeting a distinct biological pathway with preclinical evidence of neuroprotective effects. Competitors in the broader neuropathic pain arena include larger pharmaceutical firms developing various sodium channel blockers and anti inflammatory agents but Dogwood Therapeutics, Inc. aims to be the first to secure regulatory approval for a Na v 1.7 modulator specifically for chemotherapy induced neuropathy which could provide a first mover advantage in a sizable unmet market.

Dogwood Therapeutics, Inc. serves clinical investigators and trial sites that enroll patients suffering from chemotherapy induced neuropathic pain and related neuropathic conditions. In the future upon regulatory approval the company expects to sell its products to healthcare providers including oncologists anesthesiologists and primary care physicians who treat patients with chronic pain. The company also collaborates with research organizations such as the National Cancer Institute which funds the SP16 program. No specific customer names are disclosed in the filing.